EN DE
Watch Cellectis for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cellectis (ALCLS) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Cellectis stock €0.45, price €1.05, that is 57.2% below the price, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0010425595

C Cellectis logo Thin data Nov 6, 2026

Cellectis

ALCLS · PA
Very expensive, weak quality

Our calculation puts a fair price 57% below what the stock costs today.

Moderate debt
Revenue last quarter 62% below a year ago.
Fair value €0.4500 · Strongly overvalued
Quality 30/100
Weak Growth (revenue 5y +0.5 %/yr in USD)
Loss-making · -102.3% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 12/100 · thin data
Thin data
Watch Cellectis for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€11.97 €0.9000 Fair Value €0.4500 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range €0.9000 – €11.97 · fair‑value band €0.3300 – €0.6600 · the €1.05 price screens above the €0.4500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Cellectis in your weekly email

Every Wednesday you see whether Cellectis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

Show moreShow less

The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma.

Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Stock analysis

Cellectis (ALCLS) currently trades at €1.05, while our model-based Fair Value estimate is €0.4500, 57% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: €0.3300 (bear) to €0.6600 (bull), the price of €1.05 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Cellectis reported revenue of $75.9M in FY2025 versus $73.9M in FY2021, a compound +0.7%/yr. Reported net income was −$70.3M in FY2025.

Key figures

Market cap €106M Micro · P/S ratio 1.48 · EPS (TTM) €−0.5500 · Net margin −102% · Return on equity −94.5% · Return on assets (EBIT) −22.9% (5-year average) · Operating margin −341% · Revenue (TTM) $63.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −57%, ALCLS screens richer than that median.

Fair Value models

Bear €0.3300 Fair Value €0.4500 Bull €0.6600
Price €1.05 · Downside -57.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €0.3400 €0.4500 €0.6700 53
All 1 models by family
Asset-Based
NCAV (Graham) €0.3400 €0.4500 €0.6700 53

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 38
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 4/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+82.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Start year 2020 (pandemic). Over 10 years: +3.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−115.5% (2020) → −55.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALCLS screens overvalued: fair value 57% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Cellectis with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −55.2% · Below median
Profitability
Return on assets −21.7% · Below median
Net margin (12 months) −102.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −62.1% · Bottom 25%
Balance sheet
Debt / equity 0.68× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.49× · Cheaper than median
P/S (12 months) 1.77× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)66 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs ALCLS
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs ALCLS
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs ALCLS
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs ALCLS
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs ALCLS
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs ALCLS
argenx SE ARGX $927.21 $908.40 −2% vs ALCLS
CSL Limited CSL A$200.77 A$183.04 −9% vs ALCLS
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs ALCLS
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs ALCLS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cellectis: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cellectis Fair Value". https://www.fairvalue-calculator.com/stock/ALCLS

Frequently asked questions

Is Cellectis (ALCLS) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of €0.4500 versus a price of €1.05, about 57% lower (overvalued).
What is the fair value of ALCLS?
Our model-based fair value for Cellectis is €0.4500 (as of Nov 6, 2026), built from audited fundamentals. The current price: €1.05.
What is the quality score of ALCLS?
Cellectis has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cellectis (ALCLS)?
Our model-based price target is the fair value of €0.4500 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario €0.3300, optimistic scenario €0.6600. It is a calculation from audited fundamentals, not an analyst target.
What is the Cellectis stock forecast for 2026?
Our models put fair value at €0.4500, about 57% lower versus a price of €1.05 (overvalued). Cautious scenario €0.3300, optimistic scenario €0.6600. The calculation is refreshed regularly with new filings.
What is the revenue of Cellectis (ALCLS)?
Cellectis reported trailing-twelve-month revenue of about $63.8M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Cellectis (ALCLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cellectis it is €0.4500 per share (as of Nov 6, 2026), against a price of €1.05. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Cellectis stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ALCLS trades above its calculated fair value: price €1.05, fair value €0.4500, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALCLS?
No. The price is what the market pays today (€1.05); the fair value is what the company's own numbers justify (€0.4500). For Cellectis the two are €0.6010 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cellectis worth?
The market values Cellectis at about €106M (market capitalisation, as of Nov 6, 2026). Per share that is €1.05; our models calculate a fair value of €0.4500 per share.
What do the bullish and bearish scenarios say about ALCLS?
Our models span a range for Cellectis: cautious scenario €0.3300, base €0.4500, optimistic €0.6600 per share (as of Nov 6, 2026, price €1.05). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cellectis (ALCLS)?
Balance-sheet figures for Cellectis (as of Nov 6, 2026): return on equity −94.5%, debt of 0.68 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is ALCLS from its 52-week high?
Cellectis trades at €1.05, about 77% below its 52-week high of €4.57 and 12% above the low of €0.9385 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €0.4500 is for.
Which stocks are comparable to Cellectis?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cellectis stock attractive at the current price?
The data as of Nov 6, 2026: price €1.05, calculated fair value €0.4500 (−57%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALCLS calculated?
We run Cellectis through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of €0.4500 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cellectis itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cellectis (ALCLS)?
The closing price on Nov 9, 2026 was €1.05. Our model-based fair value is €0.4500, about 57% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cellectis right now?
The price sits above even our optimistic bull case (€0.6600). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.3300 to €0.6600) leaves room in how you read the outcome.

Key figures of Cellectis

How large is the market capitalisation of Cellectis (ALCLS)?
The market capitalisation of Cellectis is €106M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cellectis (ALCLS)?
The price-to-sales ratio of Cellectis is 1.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cellectis (ALCLS)?
Earnings per share at Cellectis are €−0.5500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cellectis (ALCLS)?
The net margin of Cellectis is −102% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cellectis (ALCLS)?
The return on equity (ROE) of Cellectis is −94.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cellectis (ALCLS)?
On an EBIT basis the return on assets of Cellectis is −22.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cellectis (ALCLS)?
The operating margin of Cellectis is −341% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cellectis (ALCLS)?
Revenue at Cellectis is growing −62.1% versus a year earlier (3y avg +58.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cellectis (ALCLS) generate?
The free cash flow of Cellectis is −$44.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cellectis (ALCLS) carry?
The net debt of Cellectis is $29.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cellectis in the live analysis

One click puts Cellectis on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.